Aptose Biosciences’ (APTO) Buy Rating Reaffirmed at Canaccord Genuity
Canaccord Genuity restated their buy rating on shares of Aptose Biosciences Inc. (NASDAQ:APTO) in a research note published on Saturday morning. The firm currently has a $7.00 target price on the stock.
APTO has been the topic of a number of other reports. Zacks Investment Research upgraded Aptose Biosciences from a sell rating to a hold rating in a research note on Tuesday. RBC Capital Markets restated an outperform rating on shares of Aptose Biosciences in a research note on Tuesday, September 13th. Finally, Royal Bank Of Canada restated an outperform rating and issued a $23.00 price target on shares of Aptose Biosciences in a research note on Saturday, June 25th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $12.30.
Aptose Biosciences (NASDAQ:APTO) opened at 2.40 on Friday. Aptose Biosciences has a 12-month low of $1.92 and a 12-month high of $6.40. The stock has a 50 day moving average price of $2.22 and a 200-day moving average price of $2.47. The stock’s market capitalization is $30.94 million.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned 0.43% of Aptose Biosciences as of its most recent SEC filing. Institutional investors own 19.47% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.